-
Je něco špatně v tomto záznamu ?
A versatile insulin analog with high potency for both insulin and insulin-like growth factor 1 receptors: Structural implications for receptor binding
M. Chrudinová, L. Žáková, A. Marek, O. Socha, M. Buděšínský, M. Hubálek, J. Pícha, K. Macháčková, J. Jiráček, I. Selicharová,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
MR/K000179/1
Medical Research Council - United Kingdom
MR/R009066/1
Medical Research Council - United Kingdom
NLK
Free Medical Journals
od 2008 do Před 1 rokem
Freely Accessible Science Journals
od 1905 do Před 1 rokem
PubMed Central
od 2005
Europe PubMed Central
od 2005 do Před 1 rokem
Open Access Digital Library
od 1905-10-01
Open Access Digital Library
od 1905-10-01
ROAD: Directory of Open Access Scholarly Resources
od 1905
PubMed
30213860
DOI
10.1074/jbc.ra118.004852
Knihovny.cz E-zdroje
- MeSH
- insulinu podobný růstový faktor I chemie genetika metabolismus MeSH
- inzulin agonisté metabolismus MeSH
- kinetika MeSH
- krystalografie rentgenová MeSH
- lidé MeSH
- receptor inzulinu chemie genetika metabolismus MeSH
- receptory somatomedinů chemie genetika metabolismus MeSH
- sekvence aminokyselin MeSH
- vazba proteinů MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Insulin and insulin-like growth factor 1 (IGF-1) are closely related hormones involved in the regulation of metabolism and growth. They elicit their functions through activation of tyrosine kinase-type receptors: insulin receptors (IR-A and IR-B) and IGF-1 receptor (IGF-1R). Despite similarity in primary and three-dimensional structures, insulin and IGF-1 bind the noncognate receptor with substantially reduced affinity. We prepared [d-HisB24, GlyB31, TyrB32]-insulin, which binds all three receptors with high affinity (251 or 338% binding affinity to IR-A respectively to IR-B relative to insulin and 12.4% binding affinity to IGF-1R relative to IGF-1). We prepared other modified insulins with the aim of explaining the versatility of [d-HisB24, GlyB31, TyrB32]-insulin. Through structural, activity, and kinetic studies of these insulin analogs, we concluded that the ability of [d-HisB24, GlyB31, TyrB32]-insulin to stimulate all three receptors is provided by structural changes caused by a reversed chirality at the B24 combined with the extension of the C terminus of the B chain by two extra residues. We assume that the structural changes allow the directing of the B chain C terminus to some extra interactions with the receptors. These unusual interactions lead to a decrease of dissociation rate from the IR and conversely enable easier association with IGF-1R. All of the structural changes were made at the hormones' Site 1, which is thought to interact with the Site 1 of the receptors. The results of the study suggest that merely modifications of Site 1 of the hormone are sufficient to change the receptor specificity of insulin.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028212
- 003
- CZ-PrNML
- 005
- 20190819101550.0
- 007
- ta
- 008
- 190813s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1074/jbc.RA118.004852 $2 doi
- 035 __
- $a (PubMed)30213860
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Chrudinová, Martina $u From the Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 245 12
- $a A versatile insulin analog with high potency for both insulin and insulin-like growth factor 1 receptors: Structural implications for receptor binding / $c M. Chrudinová, L. Žáková, A. Marek, O. Socha, M. Buděšínský, M. Hubálek, J. Pícha, K. Macháčková, J. Jiráček, I. Selicharová,
- 520 9_
- $a Insulin and insulin-like growth factor 1 (IGF-1) are closely related hormones involved in the regulation of metabolism and growth. They elicit their functions through activation of tyrosine kinase-type receptors: insulin receptors (IR-A and IR-B) and IGF-1 receptor (IGF-1R). Despite similarity in primary and three-dimensional structures, insulin and IGF-1 bind the noncognate receptor with substantially reduced affinity. We prepared [d-HisB24, GlyB31, TyrB32]-insulin, which binds all three receptors with high affinity (251 or 338% binding affinity to IR-A respectively to IR-B relative to insulin and 12.4% binding affinity to IGF-1R relative to IGF-1). We prepared other modified insulins with the aim of explaining the versatility of [d-HisB24, GlyB31, TyrB32]-insulin. Through structural, activity, and kinetic studies of these insulin analogs, we concluded that the ability of [d-HisB24, GlyB31, TyrB32]-insulin to stimulate all three receptors is provided by structural changes caused by a reversed chirality at the B24 combined with the extension of the C terminus of the B chain by two extra residues. We assume that the structural changes allow the directing of the B chain C terminus to some extra interactions with the receptors. These unusual interactions lead to a decrease of dissociation rate from the IR and conversely enable easier association with IGF-1R. All of the structural changes were made at the hormones' Site 1, which is thought to interact with the Site 1 of the receptors. The results of the study suggest that merely modifications of Site 1 of the hormone are sufficient to change the receptor specificity of insulin.
- 650 _2
- $a sekvence aminokyselin $7 D000595
- 650 _2
- $a krystalografie rentgenová $7 D018360
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inzulin $x agonisté $x metabolismus $7 D007328
- 650 _2
- $a insulinu podobný růstový faktor I $x chemie $x genetika $x metabolismus $7 D007334
- 650 _2
- $a kinetika $7 D007700
- 650 _2
- $a vazba proteinů $7 D011485
- 650 _2
- $a receptor inzulinu $x chemie $x genetika $x metabolismus $7 D011972
- 650 _2
- $a receptory somatomedinů $x chemie $x genetika $x metabolismus $7 D017451
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Žáková, Lenka $u From the Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Marek, Aleš $u From the Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Socha, Ondřej $u From the Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Buděšínský, Miloš $u From the Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Hubálek, Martin $u From the Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Pícha, Jan $u From the Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Macháčková, Kateřina $u From the Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Jiráček, Jiří $u From the Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Selicharová, Irena $u From the Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo n. 2, 166 10 Prague 6, Czech Republic selicharova@uochb.cas.cz.
- 773 0_
- $w MED00002546 $t The Journal of biological chemistry $x 1083-351X $g Roč. 293, č. 43 (2018), s. 16818-16829
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30213860 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190819101824 $b ABA008
- 999 __
- $a ok $b bmc $g 1433361 $s 1066672
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 293 $c 43 $d 16818-16829 $e 20180913 $i 1083-351X $m The Journal of biological chemistry $n J Biol Chem $x MED00002546
- GRA __
- $a MR/K000179/1 $p Medical Research Council $2 United Kingdom
- GRA __
- $a MR/R009066/1 $p Medical Research Council $2 United Kingdom
- LZP __
- $a Pubmed-20190813